400 related articles for article (PubMed ID: 23840000)
1. Higher incidence of acute kidney injury with intravenous colistimethate sodium compared with polymyxin B in critically ill patients at a tertiary care medical center.
Akajagbor DS; Wilson SL; Shere-Wolfe KD; Dakum P; Charurat ME; Gilliam BL
Clin Infect Dis; 2013 Nov; 57(9):1300-3. PubMed ID: 23840000
[TBL] [Abstract][Full Text] [Related]
2. Risk factors for acute kidney injury in patients treated with polymyxin B or colistin methanesulfonate sodium.
Tuon FF; Rigatto MH; Lopes CK; Kamei LK; Rocha JL; Zavascki AP
Int J Antimicrob Agents; 2014 Apr; 43(4):349-52. PubMed ID: 24439066
[TBL] [Abstract][Full Text] [Related]
3. Incidence and predictors of acute kidney injury associated with intravenous polymyxin B therapy.
Kubin CJ; Ellman TM; Phadke V; Haynes LJ; Calfee DP; Yin MT
J Infect; 2012 Jul; 65(1):80-7. PubMed ID: 22326553
[TBL] [Abstract][Full Text] [Related]
4. Multicenter Prospective Cohort Study of Renal Failure in Patients Treated with Colistin versus Polymyxin B.
Rigatto MH; Oliveira MS; Perdigão-Neto LV; Levin AS; Carrilho CM; Tanita MT; Tuon FF; Cardoso DE; Lopes NT; Falci DR; Zavascki AP
Antimicrob Agents Chemother; 2016 Apr; 60(4):2443-9. PubMed ID: 26856846
[TBL] [Abstract][Full Text] [Related]
5. Colistin-associated Acute Kidney Injury in Severely Ill Patients: A Step Toward a Better Renal Care? A Prospective Cohort Study.
Dalfino L; Puntillo F; Ondok MJ; Mosca A; Monno R; Coppolecchia S; Spada ML; Bruno F; Brienza N
Clin Infect Dis; 2015 Dec; 61(12):1771-7. PubMed ID: 26354965
[TBL] [Abstract][Full Text] [Related]
6. Nephrotoxicity of Polymyxins: Is There Any Difference between Colistimethate and Polymyxin B?
Zavascki AP; Nation RL
Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 27993859
[TBL] [Abstract][Full Text] [Related]
7. Colistin- and polymyxin-induced nephrotoxicity: focus on literature utilizing the RIFLE classification scheme of acute kidney injury.
Pike M; Saltiel E
J Pharm Pract; 2014 Dec; 27(6):554-61. PubMed ID: 25237156
[TBL] [Abstract][Full Text] [Related]
8. Nephrotoxicity associated with intravenous colistin in critically ill patients.
Doshi NM; Mount KL; Murphy CV
Pharmacotherapy; 2011 Dec; 31(12):1257-64. PubMed ID: 22122186
[TBL] [Abstract][Full Text] [Related]
9. Nephrotoxicity associated with intravenous colistin (colistimethate sodium) treatment at a tertiary care medical center.
Hartzell JD; Neff R; Ake J; Howard R; Olson S; Paolino K; Vishnepolsky M; Weintrob A; Wortmann G
Clin Infect Dis; 2009 Jun; 48(12):1724-8. PubMed ID: 19438394
[TBL] [Abstract][Full Text] [Related]
10. Nephrotoxicity in Patients with or without Cystic Fibrosis Treated with Polymyxin B Compared to Colistin.
Crass RL; Rutter WC; Burgess DR; Martin CA; Burgess DS
Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28167560
[TBL] [Abstract][Full Text] [Related]
11. Risk factors for acute kidney injury (AKI) in patients treated with polymyxin B and influence of AKI on mortality: a multicentre prospective cohort study.
Rigatto MH; Behle TF; Falci DR; Freitas T; Lopes NT; Nunes M; Costa LW; Zavascki AP
J Antimicrob Chemother; 2015 May; 70(5):1552-7. PubMed ID: 25604744
[TBL] [Abstract][Full Text] [Related]
12. Comparisons of adverse event reporting for colistin versus polymyxin B using the US Food and Drug Administration Adverse Event Reporting System (FAERS).
Truong CB; Durham SH; Qian J
Expert Opin Drug Saf; 2021 May; 20(5):603-609. PubMed ID: 33573405
[No Abstract] [Full Text] [Related]
13. Predicting the risk of nephrotoxicity in patients receiving colistimethate sodium: a multicentre, retrospective, cohort study.
Phe K; Shields RK; Tverdek FP; Aitken SL; Guervil DJ; Lam WM; Musgrove RJ; Luce AM; Tam VH
J Antimicrob Chemother; 2016 Dec; 71(12):3585-3587. PubMed ID: 27543655
[TBL] [Abstract][Full Text] [Related]
14. Polymyxin B and colistimethate are comparable as to efficacy and renal toxicity.
Oliveira MS; Prado GV; Costa SF; Grinbaum RS; Levin AS
Diagn Microbiol Infect Dis; 2009 Dec; 65(4):431-4. PubMed ID: 19733029
[TBL] [Abstract][Full Text] [Related]
15. Colistin Population Pharmacokinetics after Application of a Loading Dose of 9 MU Colistin Methanesulfonate in Critically Ill Patients.
Karaiskos I; Friberg LE; Pontikis K; Ioannidis K; Tsagkari V; Galani L; Kostakou E; Baziaka F; Paskalis C; Koutsoukou A; Giamarellou H
Antimicrob Agents Chemother; 2015 Dec; 59(12):7240-8. PubMed ID: 26369974
[TBL] [Abstract][Full Text] [Related]
16. Colistin therapy in critically ill patients with chronic renal failure and its effect on development of renal dysfunction.
Turkoglu M; Dizbay M; Ciftçi A; Aksakal FN; Aygencel G
Int J Antimicrob Agents; 2012 Feb; 39(2):142-5. PubMed ID: 22115538
[TBL] [Abstract][Full Text] [Related]
17. Incidence and risk factors of nephrotoxicity in patients on colistimethate sodium.
Hassan MM; Gaifer Z; Al-Zakwani IS
Int J Clin Pharm; 2018 Apr; 40(2):444-449. PubMed ID: 29542034
[TBL] [Abstract][Full Text] [Related]
18. Colistin nephrotoxicity increases with age.
Balkan II; Dogan M; Durdu B; Batirel A; Hakyemez IN; Cetin B; Karabay O; Gonen I; Ozkan AS; Uzun S; Demirkol ME; Akbas S; Kacmaz AB; Aras S; Mert A; Tabak F
Scand J Infect Dis; 2014 Oct; 46(10):678-85. PubMed ID: 25073536
[TBL] [Abstract][Full Text] [Related]
19. Risk Factors for Colistin-Associated Acute Kidney Injury: A Multicenter Study from Turkey.
Gul S; Kuscu F; Aydemir H; Ozturk DB; Deveci O; Duygu F; Kacmaz B; Yaman F; Aslan E
Jpn J Infect Dis; 2016; 69(2):109-12. PubMed ID: 26166495
[TBL] [Abstract][Full Text] [Related]
20. Risk factors for acute kidney injury in critically ill patients receiving high intravenous doses of colistin methanesulfonate and/or other nephrotoxic antibiotics: a retrospective cohort study.
Rocco M; Montini L; Alessandri E; Venditti M; Laderchi A; De Pascale G; Raponi G; Vitale M; Pietropaoli P; Antonelli M
Crit Care; 2013 Aug; 17(4):R174. PubMed ID: 23945197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
